September 26th, 2012
Treading Water During the Post-MI Waiting Period
Harlan M. Krumholz, MD, SM and James Fang, MD
Does your institution use the LifeVest strategy routinely during the waiting period after an MI?
September 10th, 2012
Selections from Richard Lehman’s Literature Review: September 10th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the safety risks of drugs that have gone through the FDA’s expedited approval program, a Framingham Heart Study paper on aortic stiffness in the elderly, and using CMR to detect previously undetected MI in older adults.
September 6th, 2012
Unrecognized MI: More Prevalent and Dangerous Than Previously Suspected
Larry Husten, PHD
Unrecognized myocardial infarction is more prevalent, and is associated with a worse prognosis, than may be generally understood.
August 30th, 2012
Was That an MI or Not? The Stuff of Controversy
Stewart Mann, DM (Oxon), FRCP(UK), FRACP
Stewart Mann recounts the highlights of several ESC sessions in which the Universal Definition of MI Task Force discussed the deliberations behind their latest version.
August 27th, 2012
IABP Randomized Trial Delivers a Shock
holgerthiele131
The lead author of the IABP-SHOCK II trial discusses the practical implications of his study group’s findings.
August 25th, 2012
New Universal Definition of MI Unveiled at ESC 2012
Larry Husten, PHD
The new definition specifies the troponin levels required to make a diagnosis of myocardial infarction in various situations.
August 20th, 2012
TNF Inhibitors Linked to Reduction in MI for Psoriasis Patients
Larry Husten, PHD
Psoriasis patients who take TNF inhibitors have a significant reduction in the risk for myocardial infarction (MI), according to a retrospective cohort study published in Archives of Dermatology. Although previous research suggested that the anti-inflammatory effects of methotrexate, an older therapy, may be beneficial in this population, the cardiovascular effects of TNF inhibitors had not been […]
August 13th, 2012
Selections from Richard Lehman’s Literature Review: August 13th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include using existing data for new research; normal weight, diabetes, and non-CVD death; cholesterol levels in U.S. kids; statins and diabetes; HDL-C and MI protection; statin treatment; hypertension treatment; clopidogrel and PPIs; and an analysis behind the “innovation crisis” of the pharmaceutical industry.
July 7th, 2012
New Algorithm for Patients with LBBB and Suspected MI
John W McEvoy, MB BCh BAO, Ian Neeland, MD, James De Lemos, MD and John Ryan, MD
John McEvoy reflects on the clinical scenario of selecting patients with left bundle-branch block and suspected MI for primary PCI — and on a new algorithm to help in the decision-making process. The authors who created the algorithm respond.
June 18th, 2012
Sexual Outcomes Following an MI: Let’s Talk About Sex, Doc
Emily M Abramsohn, MPH
Emily Abramsohn discusses her research on sex and mortality after an MI, and how doctors can better communicate with their patients about this issue.
NEJM Journal Watch — Recent Cardiology Articles- A Novel Device for Coronary Microvascular Dysfunction and Refractory Angina
- Modeling the Cost-Effectiveness of a Polypill to Prevent Cardiovascular Disease
- More Data on the Cognitive Safety of Very Low LDL-C Levels
- Is “As-Needed” Blood Pressure Medication Really Needed in Inpatients?
- Major and Intracranial Hemorrhage Risk with Direct Oral Anticoagulants vs. Aspirin